ArticleClinical ophthalmology (Auckland, N.Z.)2020
Safety and Efficacy of a New Posterior Chamber Phakic Intraocular Lens in Cases of High Myopia: Early Results.
Article in Clinical ophthalmology (Auckland, N.Z.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Rotational stability and visual outcomes of toric implantable collamer lenses in eyes with horizontal and non-horizontal implanting orientation: an observational study.International ophthalmology · 2026Observational
- Long-term observation of V4c implantable collamer lenses implantation for moderate to extreme high myopia correction: five years follow-up.Eye (London, England) · 2024Article
- Outcomes of refractive implantable lens implantation after deep anterior lamellar keratoplasty.Indian journal of ophthalmology · 2023Article
- Analysis of perioperative problems related to intraocular Implantable Collamer Lens (ICL) implantation.International ophthalmology · 2022Review
- Safety and anterior chamber structure of evolution implantable Collamer lens implantation with short white-to-white corneal diameters.Frontiers in medicine · 2022Article
- Five-year outcomes of EVO implantable collamer lens implantation for the correction of high myopia and super high myopia.Eye and vision (London, England) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo demonstrate the visual outcomes of a foldable, hydroxy ethyl-methacrylate, single-piece, posterior chamber phakic intraocular lens (pIOL). STUDY TYPE: Retrospective study. MATERIALS AND
methodsPatients presenting with moderate to high myopia who underwent surgical correction with a posterior chamber phakic IOL (refractive intraocular lens, phakic intraocular lens, Appasamy Associates, Chennai, India) were retrospectively reviewed. Only patients with at least one-year follow-up were included. Manifest refraction, uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), endothelial cell density (ECD), and pIOL vault were analyzed 1, 3, 6, and 12 months after surgery. Intraoperative and postoperative events were recorded in all cases.
resultsThe study included 30 eyes from 15 patients. The mean patient age was 25.8 ± 3 years. The spherical equivalent of manifest refraction was -11.47 ± 4.38 D preoperatively and -0.44 ± 0.55 D postoperatively. The preoperative CDVA was 0.17 ± 0.12 logMAR. The postoperative UDVA was 0.053 ± 0.11 logMAR (min: -0.17 and max: 0.2) and 0.019 ± 0.091 logMAR (min: -0.17 and max: 0.2) at the end of 1 month and 6 months, respectively. At the end of the 12-month visit, the postoperative UDVA was 0.032 ± 0.094, and the safety index was 2.42. The mean ECD was 2639 cells/mm
conclusionBased on postoperative experience, we found that RIL phakic IOLs are safe and effective for treating high myopia at short-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.